Literature DB >> 22092133

Dexmedetomidine attenuates remote lung injury induced by renal ischemia-reperfusion in mice.

J Gu1, J Chen, P Xia, G Tao, H Zhao, D Ma.   

Abstract

BACKGROUND: Renal ischemia-reperfusion (I/R) may cause acute lung injury (ALI). The mortality of combined acute kidney injury and ALI is extremely high. Dexmedetomidine, an α(2) adrenergic agonist, exerts potent anti-inflammatory and organoprotective effects in addition to its sedative and analgesic properties. We sought to elucidate whether dexmedetomidine can attenuate lung injury following renal I/R in a murine model of renal I/R.
METHODS: Adult C57BL/6J male mice were randomized to five groups: sham-operated control (Sham); renal I/R (I/R); intraperitoneal injection of dexmedetomidine 25 μg/kg before ischemia (pre-dex) and after perfusion (post-dex); combination of α(2) adrenergic antagonist atipamezole 250 μg/kg prior to dexmedetomidine pre-treatment (atip-dex). Kidney I/R was induced by bilateral renal pedicle clamping for 45 min and followed by 6 h reperfusion. The pulmonary tissues were harvested for histopathological evaluation, wet/dry ratio measurement, biochemical analysis of myeloperoxidase (MPO), Polymerase chain reaction (PCR) determination of Inter-cellular adhesion molecule (ICAM-1) and Tumor necrosis factor - alpha (TNF-α) mRNA.
RESULTS: Renal IR induced significant pulmonary injuries, increased wet/dry ratio together with the enhanced of MPO activities and increased ICAM-1 and TNF-α mRNA level. Both pre- and post-treatment with dexmedetomidine markedly reduced lung edema and inflammatory response and lowered MPO activity and ICAM-1 and TNF-α mRNA expression. The protective effects of dexmedetomidine in the lung were partially reversed by atipamezole, but there were no effect on ICAM-1 and TNF-α mRNA expression level.
CONCLUSIONS: Dexmedetomidine is capable of attenuating remote lung injury induced by renal IR via both α(2) adrenoceptors dependent and independent mechanisms.
© 2011 The Authors. Acta Anaesthesiologica Scandinavica © 2011 The Acta Anaesthesiologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22092133     DOI: 10.1111/j.1399-6576.2011.02526.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  51 in total

1.  The effects of dexmedetomidine on post-operative cognitive dysfunction and inflammatory factors in senile patients.

Authors:  Wenjin Chen; Bo Liu; Feng Zhang; Peng Xue; Rongsheng Cui; Weifu Lei
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Dexmedetomidine alleviates pulmonary edema by upregulating AQP1 and AQP5 expression in rats with acute lung injury induced by lipopolysaccharide.

Authors:  Yuan-Xu Jiang; Zhong-Liang Dai; Xue-Ping Zhang; Wei Zhao; Qiang Huang; Li-Kun Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

Review 3.  Mechanisms and mediators of lung injury after acute kidney injury.

Authors:  Sarah Faubel; Charles L Edelstein
Journal:  Nat Rev Nephrol       Date:  2015-10-06       Impact factor: 28.314

4.  [Protective effect of dexmedetomidine against perioperative inflammation and on pulmonary function in patients undergoing radical resection of lung cancer].

Authors:  Yuan-Bo Guo; Jin-Dong Xu; Xue-Xia Ji; Jian-Xing Zhang; Jie-Xian Liang; Guo-Bin Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-12-20

5.  Dexmedetomidine alleviates the spinal cord ischemia-reperfusion injury through blocking mast cell degranulation.

Authors:  Jun Ma; Xiao-Long Zhang; Cheng-Yu Wang; Zhi Lin; Jie-Ru Tao; Hua-Cheng Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Artesunate Inhibits Renal Ischemia Reperfusion-Stimulated Lung Inflammation in Rats by Activating HO-1 Pathway.

Authors:  Zhaohui Liu; Junjie Zhang; Shitong Li; Jihong Jiang
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

7.  The Preventive Effect of Dexmedetomidine Against Postoperative Intra-abdominal Adhesions in Rats.

Authors:  Serdar Kuru; Osman Bahadir Bozkirli; Aziz Mutlu Barlas; Mehmet Esat Duymus; Mehmet Senes; Nihat Yumusak; Cevdet Yilmaz; Kemal Kismet
Journal:  Int Surg       Date:  2015-01

8.  Dexmedetomidine controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.

Authors:  Hui Xiang; Bo Hu; Zhifeng Li; Jianguo Li
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

9.  Dexmedetomidine inhibits tumor necrosis factor-alpha and interleukin 6 in lipopolysaccharide-stimulated astrocytes by suppression of c-Jun N-terminal kinases.

Authors:  Xiaobao Zhang; Jun Wang; Wenyi Qian; Jingjing Zhao; Li Sun; Yanning Qian; Hang Xiao
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

10.  Dexmedetomidine suppresses bupivacaine-induced parthanatos in human SH-SY5Y cells via the miR-7-5p/PARP1 axis-mediated ROS.

Authors:  Ting Zheng; Chunying Zheng; Fei Gao; Fengyi Huang; Bin Hu; Xiaochun Zheng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-09-28       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.